EA202191105A1 - Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение - Google Patents
Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применениеInfo
- Publication number
- EA202191105A1 EA202191105A1 EA202191105A EA202191105A EA202191105A1 EA 202191105 A1 EA202191105 A1 EA 202191105A1 EA 202191105 A EA202191105 A EA 202191105A EA 202191105 A EA202191105 A EA 202191105A EA 202191105 A1 EA202191105 A1 EA 202191105A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- glp1
- gdf15
- peptide
- fusion proteins
- glucagon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748603P | 2018-10-22 | 2018-10-22 | |
| PCT/IB2019/059029 WO2020084496A1 (en) | 2018-10-22 | 2019-10-22 | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191105A1 true EA202191105A1 (ru) | 2021-08-03 |
Family
ID=70330680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191105A EA202191105A1 (ru) | 2018-10-22 | 2019-10-22 | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11713345B2 (https=) |
| EP (2) | EP4520343A3 (https=) |
| JP (2) | JP7539902B2 (https=) |
| KR (1) | KR20210081389A (https=) |
| CN (2) | CN119751697A (https=) |
| AU (2) | AU2019368816B2 (https=) |
| BR (1) | BR112021007376A2 (https=) |
| CA (1) | CA3116983A1 (https=) |
| CL (1) | CL2021000987A1 (https=) |
| CO (1) | CO2021005051A2 (https=) |
| CR (1) | CR20210193A (https=) |
| DO (1) | DOP2021000075A (https=) |
| EA (1) | EA202191105A1 (https=) |
| EC (1) | ECSP21028914A (https=) |
| ES (1) | ES3011982T3 (https=) |
| IL (1) | IL282297B1 (https=) |
| JO (1) | JOP20210084A1 (https=) |
| MX (1) | MX2021004665A (https=) |
| MY (1) | MY205905A (https=) |
| PE (1) | PE20211078A1 (https=) |
| PH (1) | PH12021550885A1 (https=) |
| SA (1) | SA521421825B1 (https=) |
| SG (1) | SG11202103990QA (https=) |
| WO (1) | WO2020084496A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| EA202191105A1 (ru) | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| EP3883960A4 (en) * | 2018-11-20 | 2022-11-09 | Janssen Pharmaceutica NV | GDF15 ANALOGUES AND METHODS OF USE TO REDUCE BODY WEIGHT AND/OR REDUCING FOOD INTAKE |
| WO2020185533A1 (en) * | 2019-03-08 | 2020-09-17 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| US11981718B2 (en) * | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| WO2022221291A2 (en) * | 2021-04-12 | 2022-10-20 | University Of Florida Research Foundation Incorporated | Compositions and methods for treating obesity |
| CN117750968A (zh) * | 2021-05-21 | 2024-03-22 | 株式会社柳韩洋行 | 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物 |
| CA3219645A1 (en) * | 2021-05-21 | 2022-11-24 | Yuhan Corporation | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| CN120530128A (zh) * | 2022-11-18 | 2025-08-22 | 株式会社柳韩洋行 | 双功能蛋白及其用途 |
| CN116813742A (zh) * | 2022-11-22 | 2023-09-29 | 杭州博茵生物技术有限公司 | 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用 |
| WO2024144431A1 (ru) * | 2022-12-29 | 2024-07-04 | Авва Фармасьютикалс Лтд | Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1 |
| JP2026505740A (ja) * | 2023-01-20 | 2026-02-18 | コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー | Ｇｆｒａｌを標的にするアンチセンスオリゴマー及びこの用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| US20090099031A1 (en) | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
| WO2008011446A2 (en) * | 2006-07-18 | 2008-01-24 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
| WO2009142773A2 (en) * | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| JP5444363B2 (ja) | 2008-10-31 | 2014-03-19 | セントビンセンツ ホスピタル シドニー リミテッド | 慢性腎疾患における予後判定の方法 |
| US9012719B2 (en) * | 2009-02-06 | 2015-04-21 | Syngenta Participations Ag | Modification of multidomain enzyme for expression in plants |
| TW201101990A (en) | 2009-07-08 | 2011-01-16 | zhen-zheng Huang | Plant media |
| KR20120097481A (ko) | 2009-07-20 | 2012-09-04 | 내셔날 쳉쿵 유니버시티 | 사람 혈청 알부민(ＨＳＡ)의 변이체와 컨쥬게이션된 αｖβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도 |
| WO2012091564A2 (en) * | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A cross-linking polypeptide that induces apoptosis |
| ES2666856T3 (es) | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
| EP3683228A3 (en) | 2012-01-26 | 2020-07-29 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| ES2791183T3 (es) | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
| LT2948559T (lt) | 2013-01-25 | 2018-06-25 | Janssen Biotech, Inc. | Kv1.3 antagonistai ir jų panaudojimo būdai |
| KR101993714B1 (ko) * | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| JP6475233B2 (ja) | 2013-06-20 | 2019-02-27 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| US9862752B2 (en) | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| GB201403794D0 (en) * | 2014-03-04 | 2014-04-16 | Univ Manchester | Novel antimicrobial peptides |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| RU2017101436A (ru) | 2014-06-24 | 2018-07-24 | Ново Нордиск А/С | Mic-1 слитные белки и их применение |
| AU2015296640B2 (en) | 2014-07-30 | 2020-05-21 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US10603359B2 (en) | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| EP3701969A1 (en) | 2014-10-31 | 2020-09-02 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| GB201512733D0 (en) | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| CN108697795A (zh) * | 2016-02-29 | 2018-10-23 | 伊莱利利公司 | Gfral受体疗法 |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| KR20190059312A (ko) | 2016-10-12 | 2019-05-30 | 얀센 바이오테크 인코포레이티드 | Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법 |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| EA202191105A1 (ru) | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| EP3883960A4 (en) | 2018-11-20 | 2022-11-09 | Janssen Pharmaceutica NV | GDF15 ANALOGUES AND METHODS OF USE TO REDUCE BODY WEIGHT AND/OR REDUCING FOOD INTAKE |
-
2019
- 2019-10-22 EA EA202191105A patent/EA202191105A1/ru unknown
- 2019-10-22 CN CN202411964603.3A patent/CN119751697A/zh active Pending
- 2019-10-22 CA CA3116983A patent/CA3116983A1/en active Pending
- 2019-10-22 US US17/309,114 patent/US11713345B2/en active Active
- 2019-10-22 AU AU2019368816A patent/AU2019368816B2/en active Active
- 2019-10-22 CR CR20210193A patent/CR20210193A/es unknown
- 2019-10-22 IL IL282297A patent/IL282297B1/en unknown
- 2019-10-22 JP JP2021546056A patent/JP7539902B2/ja active Active
- 2019-10-22 CN CN201980085401.2A patent/CN113226351B/zh active Active
- 2019-10-22 ES ES19875615T patent/ES3011982T3/es active Active
- 2019-10-22 KR KR1020217015121A patent/KR20210081389A/ko active Pending
- 2019-10-22 PE PE2021000543A patent/PE20211078A1/es unknown
- 2019-10-22 SG SG11202103990QA patent/SG11202103990QA/en unknown
- 2019-10-22 MY MYPI2021002147A patent/MY205905A/en unknown
- 2019-10-22 WO PCT/IB2019/059029 patent/WO2020084496A1/en not_active Ceased
- 2019-10-22 EP EP25150545.9A patent/EP4520343A3/en active Pending
- 2019-10-22 BR BR112021007376-0A patent/BR112021007376A2/pt unknown
- 2019-10-22 EP EP19875615.7A patent/EP3870211B1/en active Active
- 2019-10-22 MX MX2021004665A patent/MX2021004665A/es unknown
-
2021
- 2021-04-19 CL CL2021000987A patent/CL2021000987A1/es unknown
- 2021-04-20 CO CONC2021/0005051A patent/CO2021005051A2/es unknown
- 2021-04-21 PH PH12021550885A patent/PH12021550885A1/en unknown
- 2021-04-21 DO DO2021000075A patent/DOP2021000075A/es unknown
- 2021-04-22 JO JOP/2021/0084A patent/JOP20210084A1/ar unknown
- 2021-04-22 EC ECSENADI202128914A patent/ECSP21028914A/es unknown
- 2021-04-22 SA SA521421825A patent/SA521421825B1/ar unknown
-
2023
- 2023-06-09 US US18/332,690 patent/US12275770B2/en active Active
-
2024
- 2024-08-14 JP JP2024135217A patent/JP2024170428A/ja active Pending
-
2025
- 2025-03-06 US US19/072,966 patent/US20250197468A1/en active Pending
- 2025-04-30 AU AU2025203071A patent/AU2025203071A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202191105A1 (ru) | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение | |
| MX2021000047A (es) | Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma. | |
| BR112021020023A2 (pt) | Ligantes de conjugação melhorados | |
| MX2022006760A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| MX2021005018A (es) | Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma. | |
| MX2021000263A (es) | Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma. | |
| CO2023017754A2 (es) | Polipéptidos modificados | |
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| MX2018000697A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| EA202092419A1 (ru) | Слитые белки ростового фактора дифференцировки 15 | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| EA202190136A1 (ru) | Способ очистки антигена | |
| CL2021002757A1 (es) | Polipéptido de fusión que comprende región fc de inmunoglobulina y gdf15. | |
| MX2025010859A (es) | Polipéptidos de fusión dap10/dap12. | |
| MX2023001440A (es) | Proteinas de fusion del ligando para flt3 y metodos de uso. | |
| EP4340880A4 (en) | ANTIBODY-PEPTIDE FUSION PROTEINS FOR THE TREATMENT OF AMYLOID DISORDERS | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| EA202090143A1 (ru) | Фармацевтически приемлемые соли полипептидов и их применение | |
| DK1370284T3 (da) | Bakteriofag-medieret immunisering | |
| SG11202100087WA (en) | Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides | |
| EP4596720A3 (en) | Bacterial leader sequences for periplasmic protein expression | |
| EA202192911A1 (ru) | Бифункциональные гуманизированные анти-c5 антитела и слитые белки фактора h и их применение | |
| EP3808847A4 (en) | Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof | |
| IL317820A (en) | Fusion protein | |
| EP4482963A4 (en) | FUSE PROTEINS |